Tag
Plozasiran, targeting APOC3 mRNA, significantly lowers triglyceride levels and reduces acute pancreatitis incidence in severe hypertriglyceridemia patients, according to pooled data from two placebo-controlled trials.
The multicentre GOULASH trial reveals that high-energy nutrition in the early phase of acute pancreatitis does not improve outcomes and may increase risks of organ failure and pain relapse compared to a gradual caloric increase, leading to
The PAMORA-RAP trial suggests that naldemedine, a peripherally acting μ-opioid receptor antagonist, may reduce the risk of recurrent acute pancreatitis by nearly 50%, offering a potential first-in-class pharmacological strategy for this hig
